WEDNESDAY, May 18, 2022 (HealthDay Information)
Individuals will quickly be capable to self-test at residence to search out out whether or not they have COVID-19, the flu or one other frequent germ, respiratory syncytial virus (RSV).
The primary nonprescription check that may spot all three respiratory viral sicknesses was permitted Monday by the U.S. Meals and Drug Administration and will probably be accessible at retail shops or on-line.
“Whereas the FDA has now approved many COVID-19 assessments with no prescription, that is the primary check approved for flu and RSV, together with COVID-19, the place a person can self-identify their want for a check, order it, accumulate their pattern and ship it to the lab for testing, with out consulting a well being care skilled,” Dr. Jeff Shuren mentioned in an FDA information launch. He directs the company’s Middle for Gadgets and Radiological Well being.
With the polymerase chain response (PCR) check from North Carolina-based Labcorp, customers accumulate their very own nasal swab pattern at residence after which ship it to one of many firm’s labs to be analyzed. Typical turnaround time for outcomes is one to 2 days after the pattern arrives on the lab, in keeping with Labcorp, NBC Information reported.
Different assessments to detect a number of respiratory viruses sometimes require individuals to see a well being care supplier, who collects the nasal swab pattern and ships it to a lab for evaluation.
The Labcorp check equipment prices $169, firm spokesperson Chris Allman instructed NBC Information.
That value is not shocking since individuals are getting three assessments in a single, mentioned Jennifer Smith, an epidemiologist on the College of North Carolina at Chapel Hill’s Gillings Faculty of International Public Well being.
She instructed NBC Information that the brand new check is prone to enhance entry to testing, notably for individuals who might not be capable to go right into a clinic to get a check or for these do not feel snug getting examined.
COVID, flu and RSV trigger tens of hundreds of deaths a 12 months and a check that detects all three is “type of the Holy Grail,” Dr. Michael Mina, a former Harvard epidemiologist, instructed NBC Information. He is now the chief science officer for eMed, an organization that gives telehealth and at-home testing providers.
Discover out extra concerning the new check on the FDA.
SOURCES: U.S. Meals and Drug Administration, information launch, May 16, 2022; NBC Information
By Robert Preidt HealthDay Reporter
Copyright © 2021 HealthDay. All rights reserved.